Compare · MNMD vs VLON
MNMD vs VLON
Side-by-side comparison of Mind Medicine (MindMed) Inc. (MNMD) and Vallon Pharmaceuticals Inc. (VLON): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MNMD and VLON operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- MNMD has more recent analyst coverage (16 ratings vs 1 for VLON).
- Company
- Mind Medicine (MindMed) Inc.
- Vallon Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 0
- 0
- Recent ratings
- 16
- 1
Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.
Vallon Pharmaceuticals Inc.
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
Latest MNMD
- Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Chief Legal Officer Sullivan Mark sold $148,244 worth of shares (11,276 units at $13.15), decreasing direct ownership by 4% to 282,576 units (SEC Form 4)
- Chief Executive Officer Barrow Robert sold $339,072 worth of shares (25,791 units at $13.15), decreasing direct ownership by 3% to 778,477 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel sold $73,623 worth of shares (5,600 units at $13.15), decreasing direct ownership by 1% to 425,025 units (SEC Form 4)
- SEC Form 144 filed by Mind Medicine (MindMed) Inc.
- MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
- MindMed Announces New Employee Inducement Grant
- MindMed Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Mind Medicine (MindMed) Inc.
- Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Latest VLON
- SEC Form 424B3 filed by Vallon Pharmaceuticals Inc.
- Vallon Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B4 filed by Vallon Pharmaceuticals Inc.
- SEC Form EFFECT filed by Vallon Pharmaceuticals Inc.
- SEC Form S-1/A filed by Vallon Pharmaceuticals Inc. (Amendment)
- SEC Form S-1/A filed by Vallon Pharmaceuticals Inc. (Amendment)
- SEC Form 424B3 filed by Vallon Pharmaceuticals Inc.
- Vallon Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- SEC Form 424B3 filed by Vallon Pharmaceuticals Inc.
- Vallon Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders